Navigation Links
Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia®
Date:11/17/2010

CHICAGO, Nov. 17, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a retrospective study of nearly 375,000 type 2 diabetes patients evaluating the incidence of events related to cardiovascular disease (CVD) and all-cause hospitalizations among initiators of BYETTA® (exenatide) injection compared to initiators of other commonly used diabetes medications. These findings were presented at the American Heart Association Scientific Sessions in Chicago.

In the study, BYETTA was associated with a lower incidence of CVD-related events than insulin, thiazolidinediones (TZDs) and sulfonylureas and a comparable incidence versus metformin and Januvia® (sitagliptin). BYETTA was also associated with a lower incidence of all-cause hospitalizations than insulin, TZDs and sulfonylureas; a comparable incidence versus metformin and a higher incidence than Januvia.

The study used data accrued over nearly four years from the IMS LifeLink™ Health Plan Claims Database, comprised of medical and pharmaceutical claims for more than 65 million patients from 98 health plans across the U.S. The incidence of CVD-related events was assessed in approximately 22,000 patients who were treated with BYETTA relative to nearly 353,000 patients who were treated with other diabetes therapies. Baseline lipid levels, blood pressure, obesity and evidence of prior cardiovascular disease were higher in patients treated with BYETTA than patients treated with most other therapies.

"Heart disease and stroke account for nearly two-thirds of deaths in people with type 2 diabetes, so it is critically important for us to understand how treatment may affect cardiovascular risk, either positively or negatively," said Orville G.
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014  Valeant Pharmaceuticals International, ... that its wholly owned subsidiary, Valeant Pharmaceuticals International, will ... amount of its 6.75% Senior Notes due 2017, CUSIP ... 15, 2014 and has mailed an irrevocable notice of ... 2014, a copy of the irrevocable notice of redemption ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne ... ambulance transport services, has been selected by Inc. ... companies in America. Photo - ... Inc. 500|5000 list identifies successful, privately-held companies with ... MedicOne Medical Response, one of only two ambulance ...
(Date:9/15/2014)...  Catalist-listed QT Vascular Ltd. ("QT Vascular" or together ... of minimally invasive medical devices for the treatment of ... has enrolled the first European patients in the ENDURE ... have already been enrolled in this study with Dr. ... Auckland, New Zealand . ...
Breaking Medicine Technology:Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5
(Date:9/15/2014)... Florida is now one of several states ... a breath test could be forced to undergo a mandatory ... will prevent more people from drinking and driving. , ... rate of breathalyzer refusal. The new law is aimed to ... CBS Miami , the new Florida law requires people to ...
(Date:9/15/2014)... 2014 (HealthDay News) -- Births of multiple babies cost ... than singleton births, researchers report. The researchers suggest ... fertilization (IVF) could ease some of that burden. ... in tandem with births to older mothers and use ... University of New South Wales, Australia. Their study, ...
(Date:9/15/2014)... New York (PRWEB) September 15, 2014 ... Market Research "Spectrometry Market - Global Industry Analysis, Size, ... global spectrometry market was valued at USD 12,212.9 million ... million by 2020 at a CAGR of 7.2% from ... employed to access properties of light within specific electromagnetic ...
(Date:9/15/2014)... (HealthDay News) -- Adding chest radiation to chemotherapy allows ... and cuts recurrence rates by nearly 50 percent, European ... four-country study, the researchers recommended that chest radiotherapy be ... who respond to chemotherapy. , , Small-cell lung cancer ... accounts for roughly 13 percent of all lung cancers. ...
(Date:9/15/2014)... freshmen understand the benefits of eating healthy foods and know ... lack confidence in their ability to act on that knowledge, ... new University of Illinois study. , "The women in our ... healthful diet, especially if they had to do something physical ... strong if they were at a party or in places ...
Breaking Medicine News(10 mins):Health News:New DUI Law Makes Blood Tests Mandatory 2Health News:Study Ties Multiple Births to Higher Costs, Complications 2Health News:Study Ties Multiple Births to Higher Costs, Complications 3Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 2Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 3Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 4Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 5Health News:Chest Radiation May Help Fight Some Advanced Lung Cancers: Study 2Health News:Chest Radiation May Help Fight Some Advanced Lung Cancers: Study 3Health News:Freshman girls know how to eat healthy but lack confidence in their ability to do it 2
... 30 A new poll by the Pew Research ... while most Catholics who have heard about the issue ... , deep divisions exist between the most-observant Catholics and ... are divided over their assessment of Obama,s job performance.Conducted ...
... YORK, April 30 ProMetic Life Sciences Inc. ... Corporation of America ("SCOA") announces that it has ... ("SPI"), both wholly owned subsidiaries of Sumitomo Corporation ("Sumitomo") ... to PBI-1402 for the Japanese market.In the course of ...
... 2 diabetes may have unintended effects on the pancreas that could ... a greater risk of pancreatic cancer in long-term users, UCLA researchers ... published in the online edition of the journal Diabetes , ... found that sitagliptin, sold in pill form as Januvia, caused abnormalities ...
... Immucor, Inc. (Nasdaq: BLUD ), a ... blood transfusion industry, today announced that access to its ... 2009 Health Care Conference in New York, NY will ... Company,s presentation is scheduled for Tuesday, May 12, 2009, ...
... and strategic focus to neurovascular interventions developer.PALO ALTO, Calif., ... today that its directors elected Eric P. Milledge as ... industry experience, business acumen and leadership to Nfocus, ... break-through technologies in the dynamic field of endovascular neurosurgery," ...
... The Alzheimer,s Association Minnesota-North Dakota in collaboration with the ... The Alzheimer,s Project on May 12 at 6:00 p.m. ... be followed by a question-and-answer panel of medical experts ... disease, The Alzheimer,s Project shows there is now genuine ...
Cached Medicine News:Health News:New Poll on Obama, Catholics and the Notre Dame Commencement Finds Deep Divisions Among Catholics 2Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 2Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 3Health News:Sumitomo to Act As Advisor to ProMetic for Japanese Market 4Health News:Popular diabetes treatment could trigger pancreatitis, pancreatic cancer 2Health News:Popular diabetes treatment could trigger pancreatitis, pancreatic cancer 3Health News:Nfocus Neuromedical Elects Eric P. Milledge Chairman of Board 2Health News:The Alzheimer's Project HBO Documentary Puts Spotlight On Alzheimer's Disease; Premiere Screening at the Hennepin County Library in Downtown Minneapolis 2
... is lightweight enough to shuttle easily between ... Designed with a goldmann standard 30 cm ... with 79 locations (including 30-2, 24-2, and ... different suprathresholds out to 30. Easyfield ...
... detections of any possible ... glaucoma in the visual ... Smooth operation of kinetic ... accuracy of static and ...
Focus Toric Monthly lenses. All the advantages of Focus Monthly lenses, now available for patients with astigmatism. Recommended for daily wear. Also approved for extended wear (1-7 days)....
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
Medicine Products: